Back to Search
Start Over
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
- Source :
- The Journal of Infectious Diseases, Vol. 197, No 8 (2008) pp. 1133-1144, Emery, S, Neuhaus, J A, Phillips, A N, Babiker, A, Cohen, C J, Gatell, J M, Girard, P-M, Grund, B, Law, M, Losso, M H, Palfreeman, A, Wood, R, Østergaard, L J & Strategies for Management of Antiretroviral Therapy (SMART) Study Group 2008, ' Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study ', Journal of Infectious Diseases, vol. 197, no. 8, pp. 1133-44 . https://doi.org/10.1086/586713
- Publication Year :
- 2008
-
Abstract
- Udgivelsesdato: 2008-Apr-15 BACKGROUND: The SMART study randomized 5,472 human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts >350 cells/microL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral suppression [VS] group). In the DC group, participants started ART when the CD4+ cell count was or= 6 months (n=228) were analyzed. The following clinical outcomes were assessed: (i) opportunistic disease (OD) or death from any cause (OD/death); (ii) OD (fatal or nonfatal); (iii) serious non-AIDS events (cardiovascular, renal, and hepatic disease plus non-AIDS-defining cancers) and non-OD deaths; and (iv) the composite of outcomes (ii) and (iii). RESULTS: A total of 477 participants (228 in the DC group and 249 in the VS group) were followed (mean, 18 months). For outcome (iv), 21 and 6 events occurred in the DC (7 in ART-naive participants and 14 in those who had not received ART for >or= 6 months) and VS (2 in ART-naive participants and 4 in those who had not received ART for 6 months) groups, respectively. Hazard ratios for DC vs. VS by outcome category were as follows: outcome (i), 3.47 (95% confidence interval [CI], 1.26-9.56; p=.02); outcome (ii), 3.26 (95% CI, 1.04-10.25; p=.04); outcome (iii), 7.02 (95% CI, 1.57-31.38; p=.01); and outcome (iv), 4.19 (95% CI, 1.69-10.39; p=.002 ). CONCLUSIONS: Initiation of ART at CD4+ cell counts >350 cells/microL compared with
- Subjects :
- HPTN 052
Adult
Male
medicine.medical_specialty
HIV/*immunology
Anti-HIV Agents
MEDLINE
Human immunodeficiency virus (HIV)
HIV Infections
Kaplan-Meier Estimate
medicine.disease_cause
Drug Administration Schedule
law.invention
Cohort Studies
Randomized controlled trial
Acquired immunodeficiency syndrome (AIDS)
law
Internal medicine
medicine
Immunology and Allergy
Humans
Kaplan-Meiers Estimate
AIDS-Related Opportunistic Infections
business.industry
HIV
Anti-HIV Agents/*administration & dosage
Middle Aged
medicine.disease
Antiretroviral therapy
CD4 Lymphocyte Count
Institutional repository
Infectious Diseases
Treatment Outcome
AIDS-Related Opportunistic Infections/immunology/mortality
Immunology
Female
business
HIV Infections/*drug therapy/immunology/mortality/virology
Cohort study
Subjects
Details
- Language :
- English
- ISSN :
- 00221899
- Database :
- OpenAIRE
- Journal :
- The Journal of Infectious Diseases, Vol. 197, No 8 (2008) pp. 1133-1144, Emery, S, Neuhaus, J A, Phillips, A N, Babiker, A, Cohen, C J, Gatell, J M, Girard, P-M, Grund, B, Law, M, Losso, M H, Palfreeman, A, Wood, R, Østergaard, L J & Strategies for Management of Antiretroviral Therapy (SMART) Study Group 2008, ' Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study ', Journal of Infectious Diseases, vol. 197, no. 8, pp. 1133-44 . https://doi.org/10.1086/586713
- Accession number :
- edsair.doi.dedup.....c67f8ec74a289bf67777af0465a07097